IPO - Unite Acquisition 1 Corp.

Form Type: S-1/A

Filing Date: 2025-06-27

Corporate Action: Ipo

Type: Update

Accession Number: 000121390025058957

Filing Summary: Adaptin Bio, Inc., following a business combination with Unite Acquisition 1 Corp., is filing an amendment to its S-1 registration statement for an IPO. The prospectus indicates the resale of 8,401,481 shares of common stock by selling stockholders, alongside 2,233,083 shares issuable from warrants. The company emphasizes its pioneering biopharmaceutical technologies aimed at enabling drug transfer across barriers, particularly for treating brain cancers and other CNS disorders. The FDA has accepted its IND for APTN-101, a product candidate targeting glioblastoma, signaling progress towards clinical trials. The document identifies Adaptin as an emerging growth company and discusses multiple uncertainties and risks regarding capital, regulatory approval, market conditions, and operational dependencies that could impact its financial future.

Form Type: S-1

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: New

Accession Number: 000121390025044585

Filing Summary: Adaptin Bio, Inc. is filing a registration statement under the Securities Act of 1933 to offer shares of its common stock to the public. The registration involves the resale of up to 8,401,481 shares by selling stockholders and 2,233,083 shares through warrants held by these stockholders. The company was previously known as Unite Acquisition 1 Corp and has undergone a merger with Adaptin Bio Operating Corporation on February 11, 2025. Following the merger, notes held by certain stockholders converted into common stock. Adaptin is positioned as a biopharmaceutical company focused on a pioneering approach to improve therapeutic delivery to the brain for treating various conditions, including cancers. They have promising candidates under development, with APTN-101 leading the path toward potential FDA trials. The firm intends to pursue additional capital through public offerings, with the goal of securing funding to further develop its product pipeline and expand into new therapeutic areas. Despite its innovative approach and development strategy, the company acknowledges risks related to capital access, regulatory approvals, and competition in the biopharmaceutical industry.